Skip to: Major Marketed Products, Employees, Financials, Research and Development, Staff, Cost of New Pharmaceuticals, Awards & Recognition

  • A heritage more than 130 years strong: company founded on May 10, 1876
  • Headquarters located in Indianapolis, Indiana, U.S.A.
  • Approximately 40,217 employees worldwide
  • Approximately 7,946 employees engaged in research and development
  • Clinical research conducted in more than 50 countries
  • Research and development facilities located in 8 countries
  • Manufacturing plants located in 13 countries
  • Products marketed in 143 countries

Major Marketed Products

2005

Byetta® for type 2 diabetes for use in combination with a thiazolidinedione (2007) (in collaboration with Amylin Pharmaceuticals, Inc.)

2004

Alimta® for malignant pleural mesothelioma, for second-line treatment of non-small-cell lung cancer (NSCLC) (2004), for first-line treatment of NSCLC (2008; Europe), and in combination with cisplatin for initial treatment of advanced nonsquamous non-small cell lung cancer, a specific type of non-small cell lung cancer. Alimta is not indicated for patients who have a different type of NSCLC called squamous cell (2008; U.S.)

2004

Cymbalta® for major depressive disorder, for diabetic peripheral neuropathic pain (2004), for generalized anxiety disorder (2007), for the maintenance treatment of major depressive disorder (2007), for fibromyalgia (2008) (in collaboration with Quintiles Transnational Corp. in the U.S., Shionogi & Co. Ltd. in Japan, and with Boehringer Ingelheim elsewhere in the world)

2004

Symbyax® for bipolar depression

2004

Yentreve® for stress urinary incontinence (approved and launched outside the U.S.)

2003

Cialis® for erectile dysfunction, for once-daily use (2008)

2003

Strattera® for attention-deficit hyperactivity disorder in children, adolescents, and adults

2002

Forteo® for treatment of men and postmenopausal women with osteoporosis who are at high risk for a fracture, for the treatment of glucocorticoid-induced osteoporosis (2008; Europe)

2001

Xigris® for severe sepsis in adult patients at high risk of death

1999

Actos® for type 2 diabetes (in collaboration with Takeda outside the U.S.)

1998

Evista® for prevention of osteoporosis in postmenopausal women, for treatment of osteoporosis in postmenopausal women (1999), for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis (2007), for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer (2007)

1996

Zyprexa® for schizophrenia, for acute bipolar mania (2000), Zyprexa® Zydis® tablet (2000) for schizophrenia maintenance (2001) as combination therapy with lithium or valproate, for acute bipolar mania (2002), for bipolar maintenance (2003), rapid-acting intramuscular formulation (2004), Zyprexa® granules (2004; launched in Japan only)

1996

Humalog® Lispro Rapid Acting Insulin for treatment of type 1 and type 2 diabetes, Humalog® Mix 75/25 (1999), Humalog® Mix 50/50 (1999)

1995

Gemzar® for non-small-cell lung cancer, for pancreatic cancer (1996), for bladder cancer (1999), approved and launched outside the U.S. for metastatic breast cancer (2003), for recurrent ovarian cancer (2004), for biliary tract cancer (2006; Japan)

1995

ReoPro® for prevention of cardiac ischemic complications in patients undergoing coronary intervention, such as angioplasty for unstable angina associated with stent procedure (1997) (in collaboration with Centocor, except in Japan)

1987

Humatrope® for growth failure caused by pediatric growth hormone deficiency, for replacement therapy for adult growth hormone deficiency (1995), for short stature caused by Turner syndrome (1997), for idiopathic short stature (2003)

1983

Humulin® for type 1 and type 2 diabetes

Back to top

Employees (as of 9/30/08)

Indianapolis : 12,057
Indiana (excluding Indianapolis) : 2,192
U.S. (excluding Indiana) : 5,401
Outside U.S. : 19,831
Worldwide total : 39,481

Back to top

Financials - 2007

(dollars in millions, except per-share data)

Net sales: $18,633.5
Net income as reported: $2,953
Earnings per share as reported: $2.71
Dividends paid per share: $1.70
Capital expenditures: $1,082.4

Back to top

Research and Development

2007 Expenditures

  • $3,487 million/year
  • $290.58 million/month
  • $67.05 million/week
  • $13.72 million/workday

Increase from previous year: 11 percent
R&D as a percentage of sales: 18.7 percent

Back to top

Staff

Employees engaged in Lilly R&D activities: 7,946
Percent of total work force: 20 percent

Back to top

Cost of New Pharmaceuticals

Average cost to discover and develop a new drug: $800 million to $1.2 billion
Average length of time from discovery to patient: 10 to 15 years

Back to top

Awards & Recognition

Receiving recognition for a job well done is always a special honor. It's an affirmation that we are sustaining Lilly's heritage of service and commitment to helping others. Making a difference in people's lives is often reward enough. Nevertheless, at Lilly we are proud of the awards we have received for the accomplishments and contributions we've made in our industry and to society overall.

  • Black Enterprise “Top 40 Companies for Diversity”
  • Business Week “Best Places to Launch a Career”
  • Chronicle of Philanthropy “Most Generous Companies”
  • Fortune magazine “America’s Most Admired Companies”
  • Institutional Investor “America’s Most Shareholder-Friendly Companies”
  • Science magazine “Best Companies for Scientists”
  • The Scientist “Best Places to Work in the Industry”
  • Working Mother magazine "100 Best Companies for Working Mothers"

Back to top